A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

Interferon gamma (IFNgamma) is a critical component of the pro-inflammatory immune response that provides protection against Mycobacterium tuberculosis. In the absence of an immunological correlate of protection, antigen-specific production of IFNgamma is a commonly used marker of a protective immun...

Bibliográfalaš dieđut
Váldodahkkit:	Beveridge, N, Fletcher, H, Hughes, J, Pathan, A, Scriba, T, Minassian, A, Sander, C, Whelan, K, Dockrell, H, Hill, A, Hanekom, W, Mcshane, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2008

Geahča maid

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
Dahkki: Griffiths, K, et al.
Almmustuhtton: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
Dahkki: Griffiths, K, et al.
Almmustuhtton: (2011)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
Dahkki: Mcshane, H, et al.
Almmustuhtton: (2005)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.
Dahkki: de Cassan, S, et al.
Almmustuhtton: (2010)

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG immunized adults vaccinated with a new tuberculosis vaccine, MVA85A (Clinical and Vaccine Immunology (2010) 17, 7, (1066-1073))
Dahkki: De Cassan, S, et al.
Almmustuhtton: (2011)

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.
Dahkki: Hanekom, W, et al.
Almmustuhtton: (2008)

Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (vol 17, pg 1066, 2010)
Dahkki: de Cassan, S, et al.
Almmustuhtton: (2011)

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations
Dahkki: Hanekom, W, et al.
Almmustuhtton: (2008)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
Dahkki: Sander, C, et al.
Almmustuhtton: (2009)

Tuberculosis vaccines: present and future.
Dahkki: Minassian, A, et al.
Almmustuhtton: (2008)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Dahkki: Whelan, K, et al.
Almmustuhtton: (2009)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
Dahkki: Pathan, A, et al.
Almmustuhtton: (2007)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Dahkki: Pathan, A, et al.
Almmustuhtton: (2012)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
Dahkki: Pathan, A, et al.
Almmustuhtton: (2007)

ESAT6-induced IFNgamma and CXCL9 can differentiate severity of tuberculosis.
Dahkki: Zahra Hasan, et al.
Almmustuhtton: (2009-01-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Dahkki: Pathan, A, et al.
Almmustuhtton: (2012)

IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia.
Dahkki: Helena del Corral, et al.
Almmustuhtton: (2009-12-01)

Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations.
Dahkki: Willem A Hanekom, et al.
Almmustuhtton: (2008-07-01)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
Dahkki: Fletcher, H, et al.
Almmustuhtton: (2008)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
Dahkki: Sander, C, et al.
Almmustuhtton: (2005)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
Dahkki: Hawkridge, T, et al.
Almmustuhtton: (2008)

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
Dahkki: Dockrell, HM, et al.
Almmustuhtton: (2022)

Tuberculosis vaccines in clinical trials.
Dahkki: Rowland, R, et al.
Almmustuhtton: (2011)

Tuberculosis vaccines: current status and future prospects.
Dahkki: Fletcher, H, et al.
Almmustuhtton: (2006)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
Dahkki: Ibanga, H, et al.
Almmustuhtton: (2006)

A novel role for IkappaBzeta in the regulation of IFNgamma production.
Dahkki: Raquel M Raices, et al.
Almmustuhtton: (2009-08-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Dahkki: Kathryn T. Whelan, et al.
Almmustuhtton: (2011-01-01)

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.
Dahkki: Scriba, T, et al.
Almmustuhtton: (2012)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
Dahkki: Mcshane, H, et al.
Almmustuhtton: (2016)

Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function.
Dahkki: Dintwe, O, et al.
Almmustuhtton: (2013)

New tuberculosis vaccines can diminish as well as enhance BCG induced protection: Results from a murine model
Dahkki: Sander, C, et al.
Almmustuhtton: (2006)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Dahkki: Tameris, MD, et al.
Almmustuhtton: (2013)

Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining
Dahkki: Smith, S, et al.
Almmustuhtton: (2010)

A New Vaccine for Tuberculosis: The Challenges of Development and Deployment
Dahkki: Fletcher, H, et al.
Almmustuhtton: (2009)

Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.
Dahkki: Sander, C, et al.
Almmustuhtton: (2007)

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Dahkki: Scriba, T, et al.
Almmustuhtton: (2011)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
Dahkki: Harris, SA, et al.
Almmustuhtton: (2014)

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.
Dahkki: Tameris, M, et al.
Almmustuhtton: (2013)

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG
Dahkki: Tameris, M, et al.
Almmustuhtton: (2013)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial
Dahkki: Tameris, MD, et al.
Almmustuhtton: (2013)